Fig. 5: FSP1 is a viable therapeutic target for KRAS-mutant LUAD.

a, Overall survival of C57BL/6 J mice with orthotopic lung tumours with Fsp1^KO (n = 7) or re-expression of human FSP1, treated with either icFSP1 (n = 8) or vehicle (n = 7). b, Longitudinal lung tumour growth (measured via bioluminescence) in C57BL/6 J mice orthotopically transplanted with FSP1^WT cells and treated with either vehicle (n = 8), LIP1 (n = 7), icFSP1 (n = 8) or icFSP1 plus LIP1 (n = 8). c, Overall survival of C57BL/6 J mice with Fsp1^KO (n = 5) tumours expressing wild-type human FSP1 (FSP1^WT) or human FSP1(Q319K) (FSP1^Q319K), treated with icFSP1 (FSP1^WT: n = 5, FSP1^Q319K: n =7) or vehicle (FSP1^WT: n = 7; FSP1^Q319K: n = 7). d, Longitudinal growth of PDX LX465 tumours treated with icFSP1 (n = 10) or vehicle (n = 10) in NSG mice. Data are mean ± s.e.m. Two-way ANOVA with Tukey’s multiple comparisons test (b), two-sided Student’s t-test (d) or Kaplan–Meier simple survival analysis (a,c). Drawing in d created in BioRender. Vaughan, A. (2025) https://BioRender.com/99qhixq.

Source data